A Phase 2 interventional study of Degarelix in Prostate Neoplasm, sponsored by British Columbia Cancer Agency. Withdrawn at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by British Columbia Cancer Agency · Phase 2, Interventional, and Treatment
Site did not proceed with this study
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing degarelix in Prostatic Neoplasms — 3 open to participants now, 5 under way, 2 of them phase 3. degarelix · Prostatic Neoplasms.
Among the 64 studies testing degarelix in Prostatic Neoplasms, this one is the 61st largest by enrollment, is one of 7 that started in 2012, is one of 27 in phase 2, and was the 37th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →3 of the 64 studies testing degarelix in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
By country, each count listing its studies:
degarelix: first FDA approval 2008 (FIRMAGON), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 32 · Phase 3 25 · Phase 4 5
First in 2001; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 127 across the 64 interventional studies. Of the 51 that completed or were terminated, 34 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 64 have an industry lead sponsor. The 10 most frequent:
British Columbia Cancer Agency is the lead sponsor of 153 studies on the registry; 33 are open to participants now.
31 studies in Prostatic Neoplasms by British Columbia Cancer Agency: 5 open now, 11 under way, 1 of them phase 3. Of 12 finished, 3 (25%) have results posted.
Among the 31 studies in Prostatic Neoplasms by British Columbia Cancer Agency, this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2012, is one of 7 in phase 2, and was the 10th registered.
British Columbia Cancer Agency’s Prostatic Neoplasms studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing degarelix in Prostatic Neoplasms, from their registry updates:
Among British Columbia Cancer Agency’s 31 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
Men with castrate resistant prostate cancer who are switched from a luteinizing hormone-releasing hormone (LHRH) antagonists from a LHRH agonist will experience a fall in prostate-specific antigen (PSA).
To determine the proportion of patients with castrate resistant Prostate Cancer who have a PSA decline of ≥50% from baseline PSA when switched from an LHRH agonist to an LHRH antagonist.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.
Drug: Degarelix
Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
Also known as: Firmagon
50% fall in PSA
Proportion of patients with castrate resistant prostate cancer (CRPC) who have a PSA decline of ≥50% from baseline when switched from an LHRH agonist to an LHRH antagonist
Time frame: 8 weekly
Luteinizing hormone (LH)
Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).
Time frame: 8 weekly
Follicle stimulating hormone (FSH)
Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).
Time frame: 8 weekly
Testosterone (TT)
Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).
Time frame: 8 weekly
dehydroepiandrosterone (DHEA)
Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).
Time frame: 8 weekly
dehydroepiandrosterone-sulfate (DHEA-S)
Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).
Time frame: 8 weekly
androstenedione (AED)
Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).
Time frame: 8 weekly
dihydrotestosterone (DHT)
Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).
Time frame: 8 weekly
Start is estimated for Aug 2012; primary completion for Dec 2013, 16 months later.
How these figures are worked out, and which studies are left out of them.
Site did not proceed with this study
Site did not proceed with this study
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Degarelix
British Columbia Cancer Agency →